The Oxford Specialist Handbook of Pharmaceutical Medicine is the go-to guide for the science and practice of this wide-ranging speciality. All aspects of drug development are covered, from ideation to animal and invitro studies, early and late clinical work and principles of pharmaceutical marketing practice. The content is supported throughout with essential information around the regulatory framework which governs drug development. The second edition has been extensively revised to take account of the rapid pace of development in pharmaceutical medicine. This includes the use of both machine learning and generative artificial intelligence. As innovative study design has advanced, including with Bayesian and real-world trials, descriptions of these studies are provided in the handbook. Novel technologies including advancements in nucleic acid medicines and antibodies are also included. Designed to appeal across a broad spectrum of readers, from healthcare professionals interested in entering the pharmaceutical medicine, to seasoned drug development leaders searching for an update on a key area of practice, the Oxford Specialist Handbook of Pharmaceutical Medicine offers concise and key information in manageable and easy to read chapters. Perfect for revising for postgraduate exams, supplementing a course, or just as a helping hand in your day-to-day practice, this handbook is a must buy for anyone practicing pharmaceutical medicine.

About the Author
Phil Ambery is a Global Clinical Head in AstraZeneca, Gothenburg, Sweden. He leads clinical development of drug projects from phase 2 to launch in the cardiovascular, renal, metabolic and liver space. Over more than 20 years in Pharma he's led more than 10 clinical projects, first in GSK and now in AZ. He's passionate about teaching and education in pharma medicine and in the NHS, is a GMC associate and dual fellow of the college of physicians and faculty of pharmaceutical medicine. Adrian Kilcoyne has led drug development programmes across a range of projects in the past 20 years. He brings a wealth of experience as an editor of the handbook, having worked across diverse therapy areas and both small and large pharma. Adrian holds an MBA as well as a range of postgraduate medical qualifications. Daniel O'Connor is medically and PhD qualified and currently the Director Regulatory and Early Access Policy at The Association of the British Pharmaceutical Industry (ABPI). He joined the ABPI after 16 years at the Medicines and Healthcare products Regulatory Agency (MHRA). At the MHRA he was Deputy Director of the Innovation Accelerator and Regulatory Science. Dan has special interests in drug development, rare diseases, regulatory science, early access and health innovation. He previously held a Clinical Lecturer post at UCL and completed higher medical training in Pharmaceutical Medicine.


Book Information
ISBN 9780198842255
Author Phil Ambery
Page Count 640
Imprint Oxford University Press
Publisher Oxford University Press